Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma
Yu-Qin Song,
Hui-Lai Zhang,
Hui-Qiang Huang,
Qing-Yuan Zhang,
Hong-Mei Jing,
Chao Wang,
Chun Wu,
Dong-Hang Li,
Yu Dai,
Kathryn Humphrey,
Jun Zhu
Affiliations
Yu-Qin Song
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing
Hui-Lai Zhang
Tianjin Medical University Cancer Institute and Hospital, Tianjin
Hui-Qiang Huang
Sun Yatsen University Cancer Center, Guangzhou
Qing-Yuan Zhang
Harbin Medical University Cancer Hospital, Harbin
Hong-Mei Jing
Peking University Third Hospital, Beijing
Chao Wang
Roche (China) Holding Ltd., Shanghai
Chun Wu
Roche (China) Holding Ltd., Shanghai
Dong-Hang Li
Roche (China) Holding Ltd., Shanghai
Yu Dai
Roche RD Center (China) Ltd., Shanghai
Kathryn Humphrey
Roche Products Ltd., Welwyn Garden City, UK
Jun Zhu
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing
